SICHUAN HEXIE SHUANGMA CO.(SZ:000935) Zhi Tong Cai Jing·2025-10-16 07:47Core Viewpoint - Sichuan Shuangma (000935.SZ) announced that its subsidiary Hubei Jianxiang Biopharmaceutical Co., Ltd. has received the approval notice for the listing application of Acetate Leuprolide from the National Medical Products Administration [1] Group 1: Company Developments - Hubei Jianxiang has obtained the approval for Acetate Leuprolide, which is a Gonadotropin-Releasing Hormone (GnRH) agonist [1] - The drug is effective in suppressing the secretion of gonadotropins when administered at therapeutic doses [1] Group 2: Market Applications - Acetate Leuprolide is currently approved in China for the treatment of endometriosis, uterine fibroids, prostate cancer, estrogen receptor-positive premenopausal breast cancer, and central precocious puberty [1]